Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy

Neurosurgery

Volumn 42, Issue 4, 1998, Pages 724-729

  Hilton, David A ^a   Love, Seth ^b   Barber, Rachel ^b   Ellison, David ^c   Sandeman, David R ^b  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Astrocytoma; Cell proliferation; Ki 67; p53; Radiotherapy; Survival

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTOMA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; CEREBELLAR NEOPLASMS; CHILD; COHORT STUDIES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; POSTOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031981166     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199804000-00021     Document Type: Article

References (56)

1. Al-Sarraj S, Bridges LR: p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 9:143-149, 1995.
2. Ansari B, Coates PJ, Greenstein BD, Hall PA: In situ end-labeling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170:1-8, 1993.
3. Barbareschi M, Iuzzolino P, Pennella A, Allegranza A, Arrigoni G, Della Pama P, Doglioni C: p53 protein expression in central nervous system neoplasms. J Clin Pathol 45:583-586, 1992.
4. Bergonie J, Tribondeau L: Interpretation of some results of radiotherapy and an attempt at determining a logical technique of treatment. Radiat Res 11:587-589, 1959.
5. Bolger BS, Symonds RP, Stanton PD, MacLean AB, Burnett R, Kely P, Cooke TG: Prediction of radiotherapy response of cervical carcinoma through measurement of proliferation rate. Br J Cancer 74:1223-1226, 1996.
6. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer 53:3667-3669, 1993.
7. Chaffey JT, Hellman S: Differing responses to radiation of murine bone marrow stem cells in relation to the cell cycle. Cancer Res 31:1613-1615, 1971.
8. Chozick BS, Pezzullo JC, Epstein MH, Finch PW: Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35:831-838, 1994.
9. Chozick BS, Weiker ME, Pezzullo JC, Jackson CL, Finkelstein SD, Ambler MW, Epstein MH, Finch PW: Pattern of p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 73:406-415, 1994.
10. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB: Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value. J Neurosurg 86:121-130, 1997.
11. Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH: Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery 37:246-254, 1995.
12. Davies E, Clarke C, Hopkins A: Malignant cerebral glioma-I: Survival, disability and morbidity after radiotherapy. Br Med J 313:1507-1512, 1996.
13. Drach LM, Kammermeier M, Neirich U, Jacobi G, Kornhuber B, Lorenz R, Schlote W: Accumulation of nuclear p53 protein and prognosis of astrocytomas in childhood and adolescene. Clin Neuropathol 15:67-73, 1996.
14. Ellison DW, Gatter KC, Steart PV, Lane DP, Weller RO: Expression of the p53 protein in a spectrum of astrocytic tumors. J Pathol 168:383-386, 1994.
15. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astroocytic tumors: An immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry 59:413-419, 1995.
16. Fazekas JT: Treatment of grades I and II brain astrocytomas: The role of radiotherapy. Int J Radiat Oncol Biol Phys 2:661-666, 1977.
17. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of wild-type p53 gene. Cancer Res 54:2287-2291, 1994.
18. Gaspar LE, Fisher BJ, Macdonald DR, Le Ber DV, Halperin EC, Schold SC, Cairncross JG: Malignant glioma: Timing of response to radiation therapy. Int J Radiat Oncol Biol Phys 25:877-879, 1993.
19. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzette M, Testolin A, Bevilacqua P: Intratumoral microvessel density and p53 protein: Correlation with metastasis in head and neck squamous cell carcinoma. Int J Cancer 55:739-744, 1993.
20. Iuzzolino P, Ghimenton C, Nicolato A, Giorgiutti F, Fina P, Doglioni C, Barbareschi M: p53 protein in low-grade astrocytomas: A study with long-term follow-up. Br J Cancer 69:586-591, 1994.
21. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson ADJ: Prognostic implications of p53 protein, epidermal growth factor receptor and Ki-67 labelling in brain tumors. Br J Cancer 66:373-385, 1992.
22. Kemp CJ, Wheldon T, Balmain A: p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet 8:66-69, 1994.
23. Kleihues P, Burger PC, Scheithauer BW: Histological Typing of Tumors of the Central Nervous System. Berlin, Springer-Verlag, 1993.
24. Koga H, Zhang S, Kumanishi T, Washiyama K, Ichikawa T, Tanaka R, Mukawa J: Analysis of gene mutations in low and high grade astrocytomas by the polymerase chain reaction assisted single strand polymorphism and immunocytochemistry. Acta Neuropathol (Berl) 87:225-232, 1994.
25. Kraus JA, Bolin C, Wolf HK, Neumann J, Kindermann D, Fimmers R, Forster F, Baumann A, Schlegel U: TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer 10:143-149, 1994.
26. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastam MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495, 1992.
27. Lane DP: A death in the life of p53. Nature 362:786-787, 1993.
28. Laws ER Jr, Taylor WF, Clifton MB, Okazaki H: Neurosurgical management of low grade astrocytoma of the cerebral hemispheres. J Neurosurg 61:665-673, 1984.
29. Leibel SA, Sheline GE: Radiation therapy for neoplasms of the brain. J Neurosurg 66:1-22, 1987.
30. Leibel SA, Sheline GE, Wara WM, Boldrey EB: The role of radiation therapy in the treatment of astrocytomas. Cancer 35:1551-1557, 1975.
31. Little JB: Differential response of rapidly and slowly proliferating human cells to X-irradiation. Radiology 93:307-313, 1969.
32. Liwnicz BH, Berger TS, Liwnicz RG, Aron BS: Radiation-associated gliomas: A report of 4 cases and analysis of postradiation tumors of the central nervous system. Neurosurgery 17:436-445, 1985.
33. Louis DN: The p53 gene and protein in human brain tumours. J Neuropathol Exp Neurol 53:11-21, 1994.
34. Louis DN, von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR: Comparative study of p53 gene and protein alterations in human astrocytomas. J Neuropathol Exp Neurol 52:31-38, 1993.
35. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994.
36. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993.
37. O'Conner PM, Jackman J, Jondle D, Bhahtia K, Magrath I, Kohn KW: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776-4780, 1993.
38. Onda K, Davis RL, Shibuya M, Wilson CB, Hoshino T: Correlation between bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 74: 1921-1926, 1994.
39. Piepmeier J, Christopher S, Spencer D, Byrne T, Kim J, Knisel JP, Lacy J, Tsukerman L, Makuch R: Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 38:872-879, 1996.
40. Piatt JH, Blue JM, Schold SC, Burger PC: Glioblastoma multiforme after radiotherapy for acromegaly. Neurosurgery 13:85-89, 1983.
41. Reifenberger J, Ring G, Gies U, Cobbers JMJL, Oberstrab J, An HX, Niederacher D, Wechsler W, Reifenberger G: Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55:822-831, 1996.
42. Rostomily RC, Halligan JB, Keles GE, Berger MS: Management of adult recurrent supratentorial gliomas. Neurosurg Q 3:219-252, 1993.
43. Sallinen PK, Haapaslo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ, Helin HJ: Prognostication of astrocytoma patient survival by Ki67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174:275-282, 1994.
44. Salvati M, Artico M, Caruso R, Rocchi G, Orlando ER, Nucci F: A report of radiation-induced gliomas. Cancer 67:392-397, 1991.
45. Shaw EG, Daumas-Duport C, Scheithauer BW: Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 70:853-861, 1989.
46. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355:846-847, 1992.
47. Stewart BW: Mechanisms of apoptosis: Integration of genetic, biochemical and cellular interactions. J Natl Cancer Inst 86:1286-1296, 1994.
48. Terasima R, Tolmach LJ: X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140:490-192, 1963.
49. Twijnstra A, Taphoorn MJB, Troost J: Value of treatment of lowgrade glioma still controversial. Ned Tijdschr Geneeskd 138: 1131-1134, 1994.
50. van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Shunter WJ, Willemse PH, Aalders JG, de Vries EG: Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2 and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13:70-78, 1995.
51. van Meyel DJ, Ramsay DA, Casson AG, Keeny M, Chambers AF, Cairncross JG: p53 mutation, expression, and DNA ploidy in evolving gliomas: Evidence for two pathways of progression. J Natl Cancer Inst 86:1011-1017, 1994.
52. Volm M, Efferth T, Mattern J: Oncoprotein (c-myc, c-erbB1, c-erbB-2, c-fos) and supressor gene product (p53) expression in squamous cell carcinoma of the lung: Clinical and biological considerations. Anticancer Res 12:11-20, 1992.
53. von Deimling A, Eibl RH, Ohgaki H, Loouis DN, von Ammon K, Petersen I, Kleihues P, Chung RY, Wiestler OD, Seizinger BR: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 52:2987-2990, 1992.
54. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens JG, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980.
55. Wyllie AH: Apoptosis. Br J Cancer 67:205-208, 1993.
56. Yamada T, Ohyama H: Radiation and apoptosis. Jpn J Cancer Chemother 21:602-607, 1994.